Please assess the completion status of the following clinical trial:

Trial Title: BI 655066/ABBV-066/Risankizumab Compared to Placebo in Patients With Active Psoriatic Arthritis

Study Design Characteristics:
- Allocation: RANDOMIZED
- Intervention Model: PARALLEL
- Observational Model: None
- Primary Purpose: TREATMENT
- Time Perspective: None
- Masking: DOUBLE
- Phase: PHASE2
- Number of Arms: 5.0

Eligibility Criteria:
Inclusion criteria:~* Have psoriatic arthritis (PsA) symptoms for ≥ 6 months prior to screening, as assessed by the investigator~* Have PsA on the basis of the Classification Criteria for Psoriatic Arthritis (CASPAR) with peripheral symptoms at screening visit, as assessed by the investigator~* Have ≥ 5 tender joints and ≥ 5 swollen joints at screening and randomisation visits, as assessed by the investigator~* At least one psoriasis (PsO) lesion or a documented personal history of PsO at screening, as assessed by the investigator~* If patients receive concurrent PsA treatments, these need to be on stable doses~* Active PsA that has been inadequately controlled by standard doses of non-steroidal anti-inflammatory drugs (NSAIDs) administered for ≥ 4 weeks, or traditional disease-modifying anti-rheumatic drugs (DMARDs) (including sulfasalazine) administered for ≥ 3 months, or tumor necrosis factor inhibitor (TNFi) agents, or subjects are intolerant to NSAIDs or DMARDs or tumor necrosis factor inhibitor (TNFi) agents, as assessed by the investigator~Exclusion criteria:~* Major chronic inflammatory or connective tissue disease other than PsA (e.g. rheumatoid arthritis, systemic lupus erythematosus, ankylosing spondylitis, Lyme disease, gout) and fibromyalgia, as assessed by the investigator~* Has received any therapeutic agent directly targeted to interleukin 12/23 (IL-12/23) (including ustekinumab), IL-23 or IL-17 (including secukinumab)~* Prior use of more than two different TNFi agents~* Use of the following treatments: TNFi agents within 12 weeks, etanercept within 8 weeks, leflunomide without cholestyramine wash-out within 8 weeks, systemic non-biologic medications for psoriatic arthritis or psoriasis and photochemotherapy within 4 weeks, intraarticular injections (including steroids) and intramuscular or intravenous corticosteroid treatment within 4 weeks, topical psoriasis medications and phototherapy within 2 weeks, low and high potency opioid analgesics within 2 weeks prior to randomisation~* Plans for administration of live vaccines during the study period or within 6 weeks prior to randomisation~* History of allergy/hypersensitivity to a systemically administered biologic agent or its excipients~* Active systemic infections during the last 2 weeks (exception: common cold) prior to randomisation, as assessed by the investigator~* Chronic or relevant acute infections including HIV, viral hepatitis and (or) active tuberculosis (TB). Patients with a positive QuantiFERON TB or purified protein derivate (PPD) test may participate in the study if further work up (according to local practice/guidelines) establishes conclusively that the patient has no evidence of active TB.~* Any documented active or suspected malignancy or history of malignancy within 5 years prior to screening, except appropriately treated basal or squamous cell carcinoma of the skin or in situ carcinoma of uterine cervix~* Major surgery performed within 12 weeks prior to randomisation or planned within 32 weeks after randomisation (e.g. hip replacement, aneurysm removal, stomach ligation), as assessed by the investigator~* Total white blood count (WBC) \< 3,000/µL, or platelets \< 100,000/µL or neutrophils \< 1,500/µL, or hemoglobin \< 8.5 g/dL at screening~* Aspartate aminotransferase (AST) or alanine aminotransferase (ALT) \> 2x the upper limit of normal, or serum direct bilirubin ≥ 1.5 mg/dL at screening~* Positive rheumatoid factor or anti-cyclic-citrullinated peptide (anti-CCP) antibodies at screening

- Gender: ALL
- Minimum Age: 18 Years
- Maximum Age: None
- Healthy Volunteers: f

Study Arms:
- Placebo (Type: PLACEBO_COMPARATOR): Participants randomized to receive double-blind (DB) placebo for risankizumab by subcutaneous (SC) injection every 4 weeks for 16 weeks.
- Risankizumab 150 mg Every 4 Weeks (Type: EXPERIMENTAL): Participants randomized to receive double-blind (DB) risankizumab 150 mg by subcutaneous (SC) injection every 4 weeks for 16 weeks.
- Risankizumab 150 mg Weeks 0, 4, and 16 (Type: EXPERIMENTAL): Participants randomized to receive double-blind (DB) risankizumab 150 mg by subcutaneous (SC) injection at Weeks 0, 4, and 16.
- Risankizumab 150 mg Weeks 0 and 12 (Type: EXPERIMENTAL): Participants randomized to receive double-blind (DB) risankizumab 150 mg by subcutaneous (SC) injection at Weeks 0 and 12.
- Risankizumab 75 mg Week 0 (Type: EXPERIMENTAL): Participants randomized to receive double-blind (DB) risankizumab 75 mg by subcutaneous (SC) injection at Week 0.

Based on this trial design, predict the completion outcome and termination type (if applicable).

Answer: outcome: complete